Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01)

Annals of Oncology

Volumn 17, Issue 8, 2006, Pages 1269-1274

  Vergnenegre, A ^a   Combescure, C ^b   Fournel, P ^c   Bayle, S ^d   Gimenez, C ^e   Souquet, P J ^f   Lena, H ^g   Perol, M ^f   Delhoume, J Y ^h   Blanchon, F ⁱ   Grivaux, M ⁱ   Bonnaud, F ⁱ   Boutin, C ⁱ   Astoul, Ph ⁱ   Carles, P ⁱ   Pujazon, M C ⁱ   Refregier, M ⁱ   Chavaillon, J M ⁱ   Guerin J C ⁱ   Kleisbauer, J P ⁱ   Thomas, P ⁱ   Le Caer, H ⁱ   Paillotin, D ⁱ   Nouvet, G ⁱ   Thiberville, L ⁱ   Poirier, R ⁱ   Le Treut, L ⁱ   Riou, R ⁱ   Robinet, G ⁱ   Geriniere L ⁱ   Taytard, A ⁱ   Vernejoux, J M ⁱ   Pacheco, Y ^j   Dussopt Guibal, S ^j   Arpin, D ⁱ   Auberger, R ⁱ   Marichy, C ⁱ   Silvani, J A ⁱ   Bonnamour, C ⁱ   Suchaud, J P ⁱ   Falchero, L ⁱ   Coetmeur, D ⁱ   Dansin, E ⁱ   Mayer, V ⁱ   Bombaron, P ⁱ   Benchalal, M ⁱ   Berard H ⁱ   more..

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h CHU de Périgueux   (France)

ⁱ CHU de Périgueux ^*

^j CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

Clinical trial; Cost minimization analysis; Lung cancer; Radiochemotherapy; Stage III NSCLC

Indexed keywords

CISPLATIN; ETOPOSIDE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DRUG DOSE REGIMEN; ECONOMIC EVALUATION; ESOPHAGITIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION; LENGTH OF STAY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; THROMBOCYTOPENIA;

EID: 33747877117     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl100     Document Type: Article

References (42)

1. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-1100.
2. Boyer M. The economics of lung cancer. Lung Cancer 1996; 14: 13-17.
3. Bishop JF, Macarounas-Kirchman K. The pharmacoeconomics of cancer therapies. Semin Oncol 1997; 24 (Suppl 19): 106-111.
4. Drummond MF, Stoddart GL, Torrance GW. Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press 1990.
5. Lebrun T, Selke B, Bercez C et al. Evaluation médico-économique en cancérologie. Bull Cancer 1997; 84: 543-546.
6. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: A review. J Clin Oncol 1998; 16: 3900-3912.
7. Evans WK, Will BP, Berthelot JM, Wolfson MG. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995; 72: 1270-1277.
8. Evans WK, Will BP, Berthelot JM, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol 1995; 5: 408-419.
9. Desch CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer patients. Curr Opin Oncol 1996; 8: 126-132.
10. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer 1994; 1: 60-65.
11. Chouaïd C, Molinier L, Combescure C et al. Economics of the clinical management of lung cancer in France : An analysis using a Markov model. Br J Cancer 2004; 90: 397-402.
12. Evans WK. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: An estimate using the Population Health Model lung cancer module. Semin Oncol 1997; 24 (2 Suppl 7): 56-63.
13. Evans WK, Will BP, Berthelot JM, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997; 15: 3038-3048.
14. Earle CC, Evans WK. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999; 80: 815-820.
15. Hillner BE, McDonald MK, Desch CE et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol 1998; 16: 1420-1424.
16. Vergnenegre A, Perol M, Pham E. Cost analysis of hospital treatment - two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Francais Pneumo Cancerologie). Lung Cancer 1996; 14: 31-44.
17. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80: 215-218.
18. Trodella L, Granone P, Valente S et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: Long-term results according to downstaging. Ann Oncol 2004; 15: 389-398.
19. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
20. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004; 46: 87-98.
21. Fournel P, Robinet G, Thomas P et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (GLOT GFPC NCP 95-01 study). J Clin Oncol 2005; 23: 5910-5917.
22. Curran WJ, Scott CB, Langer R et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG. In ASCO: Proc Am Soc Clin Oncol, Chicago 2003; 621.
23. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147-154.
24. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-721.
25. White TJ, Arakelian A, Rho JP. Counting the costs of drug related adverse events. Pharm Economics 1999; 15: 445-458.
26. Ministère. de la Santé - Echelle nationale des coûts 1999. http://www.atih.sante.fr.
27. Roberts RR, Frutos PW, Ciavarella GG et al. Distribution of variable versus fixed costs of hospital care. J Am Med Assoc 1999; 281: 644-649.
28. UCANSS. Nomenclature Générale des Actes Professionnels des Médecins, Chirurgiens-dentistes, Sages-femmes et Auxillaires médicaux. Nomenclatue des actes de biologie médicale. CNAMTS 2003; 1 vol: 518.
29. Ministère de la Santé. Avenant no2 à la convention nationale des transporteurs sanitaires privés. Journal Officiel 15/06/2002: 10596-10598.
30. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197-1200.
31. Hill C, Com-Nougué C, Kramar A et al. Analyse statistique des données de survie. Paris: Médecine-Sciences, Flammarion 1996; 190.
32. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometries 1997; 53: 419-434.
33. Etzioni RD, Feuer EJ, Sullivan SD et al. On the use of survival analysis techniques to estimate medical care costs. J Health Econ 1999; 18: 365-380.
34. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
35. Koopmannschap MA, Rutten FH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-466.
36. Launois R, Croutsche JJ, Megnigbeto AC et al. L'apport indispensable de l'épidémiologie clinique aux modèles de Markov. J Econ Med 1999; 17: 343-361.
37. Fournel P, Perol M, Robinet G et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). In ASCO: Proc Am Soc Clin Oncol 2001; 1246.
38. Schiller J, Tilden D, Aristides M et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004; 43: 101-112.
39. Ramsey SD, Moinpour CM, Lovato LC et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 291-297.
40. Evans WK, Will BP, Berthelot J. Cost-effectiveness of lung cancer treatment. In Hensen HH (ed.): Textbook on Lung Cancer. London: Mosby 2000; 349-362.
41. Vokes EE. Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol 2005; 23: 5853-5855.
42. Movsas B. Will future progress in non-small-cell lung cancer be step by step... or by leaps and bounds? J Clin Oncol 2005; 23: 5859-5861.